title: Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.
abstract: BACKGROUND
  Artemisinin-resistant Plasmodium falciparum has been reported in Pailin, western Cambodia, detected as a slow parasite clearance rate in vivo. Emergence of this phenotype in western Thailand and possibly elsewhere threatens to compromise the effectiveness of all artemisinin-based combination therapies. Parasite genetics is associated with parasite clearance rate but does not account for all variation. We investigated contributions of both parasite genetics and host factors to the artemisinin-resistance phenotype in Pursat, western Cambodia.
  
  
  METHODS
  Between June 19 and Nov 28, 2009, and June 26 and Dec 6, 2010, we enrolled patients aged 10 years or older with uncomplicated falciparum malaria, a density of asexual parasites of at least 10,000 per μL of whole blood, no symptoms or signs of severe malaria, no other cause of febrile illness, and no chronic illness. We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h. We assessed parasite density on thick blood films every 6 h until undetectable. The parasite clearance half-life was calculated from the parasite clearance curve. We genotyped parasites with 18 microsatellite markers and patients for haemoglobin E, α-thalassaemia, and a mutation of G6PD, which encodes glucose-6-phosphate dehydrogenase. To account for the possible effects of acquired immunity on half-life, we used three surrogates for increased likelihood of exposure to P falciparum: age, sex, and place of residence. This study is registered with ClinicalTrials.gov, number NCT00341003.
  
  
  RESULTS
  We assessed 3504 individuals from all six districts of Pursat province seeking treatment for malaria symptoms. We enrolled 168 patients with falciparum malaria who met inclusion criteria. The geometric mean half-life was 5·85 h (95% CI 5·54-6·18) in Pursat, similar to that reported in Pailin (p=0·109). We identified two genetically different parasite clone groups: parasite group 1 (PG1) and parasite group 2 (PG2). Non-significant increases in parasite clearance half-life were seen in patients with haemoglobin E (0·55 h; p=0·078), those of male sex (0·96 h; p=0·064), and in 2010 (0·68 h; p=0·068); PG1 was associated with a significant increase (0·79 h; p=0·033). The mean parasite heritability of half-life was 0·40 (SD 0·17).
  
  
  CONCLUSIONS
  Heritable artemisinin resistance is established in a second Cambodian province. To accurately identify parasites that are intrinsically susceptible or resistant to artemisinins, future studies should explore the effect of erythrocyte polymorphisms and specific immune responses on half-life variation.
  
  
  BACKGROUND
  Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
authors.affiliation: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
authors.forename: Chanaki
authors.initials: C
authors.lastname: Amaratunga
authors.forename: Sokunthea
authors.initials: S
authors.lastname: Sreng
authors.forename: Seila
authors.initials: S
authors.lastname: Suon
authors.forename: Erika S
authors.initials: ES
authors.lastname: Phelps
authors.forename: Kasia
authors.initials: K
authors.lastname: Stepniewska
authors.forename: Pharath
authors.initials: P
authors.lastname: Lim
authors.forename: Chongjun
authors.initials: C
authors.lastname: Zhou
authors.forename: Sivanna
authors.initials: S
authors.lastname: Mao
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Anderson
authors.forename: Niklas
authors.initials: N
authors.lastname: Lindegardh
authors.forename: Hongying
authors.initials: H
authors.lastname: Jiang
authors.forename: Jianping
authors.initials: J
authors.lastname: Song
authors.forename: Xin-zhuan
authors.initials: XZ
authors.lastname: Su
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: White
authors.forename: Arjen M
authors.initials: AM
authors.lastname: Dondorp
authors.forename: Tim J C
authors.initials: TJ
authors.lastname: Anderson
authors.forename: Michael P
authors.initials: MP
authors.lastname: Fay
authors.forename: Jianbing
authors.initials: J
authors.lastname: Mu
authors.forename: Socheat
authors.initials: S
authors.lastname: Duong
authors.forename: Rick M
authors.initials: RM
authors.lastname: Fairhurst
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000494:pharmacology; D037621:Artemisinins / Q000008:administration & dosage* / Q000494:pharmacology; D002160:Cambodia / Q000453:epidemiology; D004351:Drug Resistance; D005260:Female; D005838:Genotype; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D015767:Mefloquine / Q000008:administration & dosage; D018895:Microsatellite Repeats; D010963:Plasmodium falciparum / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin; D005954:Glucosephosphate Dehydrogenase; D015767:Mefloquine